Advertisement

Journal of Endocrinological Investigation

, Volume 18, Issue 11, pp 869–871 | Cite as

Early occurrence of a thyroid carcinoma in a patient who developed Graves’ disease after treatment for Hodgkin’s disease

  • Antonino Belfiore
  • G. Pellegriti
  • G. Milone
  • G. Vigneri
  • P. Gangemi
  • A. Fiumara
  • R. Vigneri
Case Report

Abstract

We report the case of a patient who developed Graves’ disease and a papillary thyroid cancer only 5 years after irradiation and adjuvant chemotherapy for Hodgkin’s disease. This case is peculiar for the very short latency time between Hodgkin’s disease treatment and thyroid cancer development, an event possibly related to Graves’ disease with elevated serum levels of TSAb. We conclude that, in patients treated for Hodgkin’s disease, continued follow-up by clinical examination and sonography of the thyroid is needed, especially if they develop Graves’ disease.

Key-words

Thyroid cancer Graves’ disease Hodgkin’s disease radiotherapy chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nelson D.F., Reddy K.V., O’Mara R.E., Rubin P. Thyroid abnormalities following neck irradiation for Hodgkin’s disease. Cancer 42: 2553, 1978.PubMedCrossRefGoogle Scholar
  2. 2.
    Hancock S.L., Cox R., McDougall I.R. Thyroid diseases after treatment of Hodgkin’s disease. N. Engl. J. Med. 325: 599, 1991.PubMedCrossRefGoogle Scholar
  3. 3.
    Kaldor J.M., Day N.E., Band P., Choi N.W., Clarke E.A., Coleman M.P., Hakama M., Koch M., Langmark F., Neal F.E. Second malignancies following testicular cancer, ovarian cancer, and Hodgkin’s disease: an international collaborative study among cancer registries. Int. J. Cancer 39: 571, 1987.PubMedCrossRefGoogle Scholar
  4. 4.
    Tucker M.A., Coleman C.N., Cox R.S., Varghese A., Rosemberg S.A. Risk of second cancers after treatment for Hodgkin’s disease. N. Engl. J. Med. 318: 76, 1988.PubMedCrossRefGoogle Scholar
  5. 5.
    Santoro A., Bonadonna G., Bonfante V., Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N. Engl. J. Med. 306: 770, 1982.PubMedCrossRefGoogle Scholar
  6. 6.
    Belfiore A., Garofalo M.R., Giuffrida D., Runello F., Filetti S., Fiumara A., Ippolito O., Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J. Clin. Endocrinol. Metab. 70: 830, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    Farbota L.M., Calandra D.B., Lawrence A.M., Paloyan E. Thyroid carcinoma in Graves’ disease. Surgery 98: 1148, 1985.PubMedGoogle Scholar
  8. 8.
    Mazzaferri E.L. Thyroid cancer and Graves’ disease. J. Clin. Endocrinol. Metab. 70: 826, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Farid N.R., Shi Y., Zou M. Molecular basis of thyroid cancer. Endocr. Rev. 15: 202, 1994.PubMedGoogle Scholar
  10. 10.
    Hales I.B., McElduff A., Crummer P., Clifton-Bligh P., Delbridge L., Hoschl R., Pole A., Reeve T.S., Wilmshurst E., Wiseman J. Does Graves’ disease or thyrotoxicosis affect the prognosis of thyroid cancer. J. Clin. Endocrinol. Metab. 75: 886, 1992.PubMedGoogle Scholar
  11. 11.
    Filetti S., Belfiore A., Amir S.M., Daniels G.H., Ippolito O., Vigneri R., Ingbar S. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N. Engl. J. Med. 318: 753, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1995

Authors and Affiliations

  • Antonino Belfiore
    • 1
  • G. Pellegriti
    • 1
  • G. Milone
    • 2
  • G. Vigneri
    • 1
  • P. Gangemi
    • 3
  • A. Fiumara
    • 3
  • R. Vigneri
    • 1
  1. 1.Cattedra di Endocrinologia, Ospedale GaribaldiCataniaItaly
  2. 2.Istituto di Ematologia, Ospedale Ferrarotto, University of CataniaCatania, andItaly
  3. 3.Servizio di Anatomia PatologicaOspedale V. EmanueleCataniaItaly

Personalised recommendations